ホーム>>Lipids>> Glycerophospholipids>>Oleoyl 3-carbacyclic Phosphatidic Acid

Oleoyl 3-carbacyclic Phosphatidic Acid (Synonyms: 3ccPA 18:1)

カタログ番号GC44500

環状ホスファチジン酸(cPAs)は、sn-2水酸基がsn-3リン酸と5員環を形成することで、リゾホスファチジン酸(LPA)の自然発生アナログです。

Products are for research use only. Not for human use. We do not sell to patients.

Oleoyl 3-carbacyclic Phosphatidic Acid 化学構造

Cas No.: 779333-58-3

サイズ 価格 在庫数 個数
500μg
$104.00
在庫あり
1mg
$199.00
在庫あり
5mg
$836.00
在庫あり
10mg
$1,463.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Cyclic phosphatidic acids (cPAs) are naturally occurring analogs of lysophosphatidic acid (LPA) in which the sn-2 hydroxy group forms a 5-membered ring with the sn-3 phosphate. Carba-derivatives of cPA (ccPA) are modified at the sn-2 (2-ccPA) or sn-3 (3-ccPA) linkage, preventing the opening of cPA to produce lysophosphatidic acid (LPA). Oleoyl 3-Carbacyclic Phosphatidic Acid (3-ccPA 18:1) is a cyclic LPA analog that contains the 18:1 fatty acid, oleate, at the sn-1 position of the glycerol backbone. At 25 μM, it inhibits the transcellular migration of MM1 cells across mesothelial cell monolayers in response to fetal bovine serum (90.1%) or LPA (99.9%) without affecting proliferation. 3-ccPA 18:1, at 0.1-1.0 μM, significantly inhibits autotaxin, an enzyme that is important in cancer cell survival, growth, migration, invasion, and metastasis.

レビュー

Review for Oleoyl 3-carbacyclic Phosphatidic Acid

Average Rating: 5 ★★★★★ (Based on Reviews and 13 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Oleoyl 3-carbacyclic Phosphatidic Acid

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.